Insights

Blog articles for PHASE Scientific USA

May is Women’s Health Month

Every household has a person with the job description of “chief medical officer.” While not an official title, the job involves researching and deciding the best healthcare action for the family. There is an excellent chance this person is not a healthcare professional and, in most households, is a woman. According […]

May is Women’s Health Month2023-05-19T01:06:50+05:00

INDICAID DETECTS COVID-19 OMICRON VARIANTS WITH GREATER SENSITIVITY THAN OTHERS

Test recognizes new COVID omicron variant XBB.1.16 which is seeing a rise throughout the United States

(GARDEN GROVE, CA,) – April 18th, 2023 – PHASE Scientific Americas, a fast-growing biotechnology company, announces that its successful at-home rapid molecular INDICAID® COVID-19 Rapid Antigen At-Home Test now recognizes the new […]

INDICAID DETECTS COVID-19 OMICRON VARIANTS WITH GREATER SENSITIVITY THAN OTHERS2023-04-21T01:02:54+05:00

NURSING AND THE DX EVOLUTION

March 23, 2023

The pandemic accelerated transformation in nursing and diagnostics. One result? The healthcare sector needs to better train the next generation of nurses on how to use new diagnostic technologies and how to counsel patients on the tests and findings. Health educators have taken note…and action.

When Nursing and Diagnostics Intersect

Through […]

NURSING AND THE DX EVOLUTION2023-03-23T00:21:25+05:00

THE DIAGNOSTIC PARTNER: ADDRESSING THE EQUITY IMPLICATIONS OF HEALTH DIAGNOSTICS

February 27, 2023

Achieving health equity, in which everyone has a fair and just opportunity to attain their highest level of health, requires ongoing efforts to address historical and contemporary injustices, overcome barriers to healthcare access, and eliminate preventable health disparities. When it comes to diagnostics, the COVID-19 pandemic cast a harsh […]

THE DIAGNOSTIC PARTNER: ADDRESSING THE EQUITY IMPLICATIONS OF HEALTH DIAGNOSTICS2023-02-28T20:42:34+05:00

THE DIAGNOSTIC PARTNER: EXPANDING THE USE OF TEST-TO-TREAT IN THE POST-PANDEMIC WORLD

February 20, 2023

The federal COVID-19 Test-to-Treat program launched in March 2022 but the test-to-treat response to infectious disease isn’t new.  It does need renewal, however.

Test-to-treat describes an early intervention approach to infectious disease in which a patient gets tested as soon as possible and, if positive, promptly receives an appropriate treatment.  […]

THE DIAGNOSTIC PARTNER: EXPANDING THE USE OF TEST-TO-TREAT IN THE POST-PANDEMIC WORLD2023-03-22T19:15:59+05:00

OMICRON VARIANT UPDATE

November 21, 2022

Phase Scientific continuously monitors emerging variants of the virus that causes COVID-19 and how their mutations may impact the performance of the INDICAID® COVID-19 Rapid Antigen Test.

An independent evaluation by the National Institutes of Health (NIH) RADx Variant Task Force has determined that the INDICAID® test detects the […]

OMICRON VARIANT UPDATE2022-12-15T22:32:18+05:00

Targeting COVID-19 Absenteeism with Test to Treat Approach

By Doug Field, Chief Revenue Officer, PHASE Scientific Americas

While the recent surges of current COVID-19 variants are not driving high levels of hospitalization and death, the persistent, circulating virus continues to affect employees and spike absenteeism across businesses of all sizes. The impact is serious, affecting not only day-to-day operations and productivity […]

Targeting COVID-19 Absenteeism with Test to Treat Approach2022-12-21T03:00:20+05:00

INDICAID’S Omicron Variant Update

INDICAID’s Omicron BA.2 Variant Update

April 04, 2022

Phase Scientific continuously monitors emerging variants of the virus that causes COVID-19 and how their mutations may impact the performance of the INDICAID® COVID-19 Rapid Antigen test. A sub-variant of Omicron designated BA.2 (B.1.1529.2) was detected in the U.S. in January 2022, and the Centers […]

INDICAID’S Omicron Variant Update2022-04-13T20:57:40+05:00
Go to Top